| A05745 | |
|
|
|
| ¥106,596.00 | |
|
|
|
|
|
|
| Ask us a question | |
| Specificity | The product is specific for DXd and DXd structurally similar molecules. The antibody can bind to DS-8201a. |
| Host Species | Mouse |
| Immunogen | DXd-KLH |
| Conjugate | Horseradish peroxidase (HRP) |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||
|
|||||
| Form | Liquid |
| Storage Buffer | Supplied in PBS (pH 7.4), 10 mg/mL BSA, 0.01% thimerosal and 50% glycerol. |
| Concentration | 0.5 mg/mL |
| Storage Instructions | The product remains stable for 1 year at -20 °C from date of receipt. Avoid repeated freezing and thawing cycles.. |
| Purification | Protein A affinity column |
| Isotype | Mouse IgG2b, κ |
| Clonality | Monoclonal |
| Clone ID | 39F4 |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
| Target Background | Payloads are the important components of antibody-drug conjugates (ADCs). The most commonly used ADC payloads are MMAE, DM1, and DXd. ADC pharmacokinetic (PK) studies include free payload analysis, conjugated antibody analysis, and total antibody analysis via ligand-binding assay (LBA) and LC-MS/MS assay. The anti-payload antibody is a useful reagent in PK assay for determining conjugated antibodies. It can be used as a capture antibody to determine the conjugated antibody in LBA assay or through immunocapture to enrich the ADC sample in LC-MS/MS assay. The DXd, also known as exatecan derivative, is a potent inhibitor of DNA topoisomerase I. Trastuzumab deruxtecan (T-DXd, DS-8201a or Enhertu®), composed of trastuzumab conjugated to DXd, is the first approved ADC for the treatment of breast cancer. |
| Synonyms | Dxd, OQM5SD32BQ, UNII-OQM5SD32BQ, Exatecan derivative, Exatecan derivative for ADC |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
